Samphire Neurosciences

Samphire Neurosciences is a private, commercial-stage biotech/medtech hybrid targeting the neuroscience of women's health. Its core platform consists of wearable neurostimulation devices (Nettle™/Lutea™) paired with a cycle-tracking software service (CycleSync™), offering a holistic, non-pharmacological solution for conditions like PMS, PMDD, and dysmenorrhea. The company is already generating revenue through direct-to-consumer sales of its hardware and subscription software, supported by claims of clinical validation from its own studies. It operates in the high-growth femtech and digital therapeutics space, competing against both traditional pharmaceuticals and wellness products.

Integrated neurotechnology platform combining non-invasive wearable neurostimulation (Nettle™/Lutea™ device) with a digital therapeutic software application (CycleSync™) for menstrual cycle tracking and symptom management. The platform leverages neuroplasticity to modulate brain activity in response to hormonal fluctuations.

Samphire competes in a fragmented landscape including traditional pharmaceutical companies (e.g., SSRIs for PMDD, hormonal therapies), generic pain relievers, consumer wellness brands offering supplements and lower-cost TENS units, and a growing number of digital health apps for cycle tracking. Its primary differentiation is the claim of a clinically-validated, brain-targeted, non-hormonal medical device.